Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03493165
Expanded Access Status : Available
First Posted : April 10, 2018
Last Update Posted : July 2, 2021
Sponsor:
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio

Brief Summary:
Single patient treatment with everolimus.

Condition or disease Intervention/treatment
Uterine Sarcoma Drug: Everolimus

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
Official Title: Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)



Intervention Details:
  • Drug: Everolimus
    mTOR inhibitor
    Other Name: Zortress, Afinitor, and Afinitor Disperz

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03493165


Contacts
Layout table for location contacts
Contact: John Sarantopoulos, MD 210-450-1785 sarantopoulo@uthscsa.edu

Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Layout table for additonal information
Responsible Party: The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT03493165    
Other Study ID Numbers: CTMS# 18-0020
First Posted: April 10, 2018    Key Record Dates
Last Update Posted: July 2, 2021
Last Verified: June 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Everolimus
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs